AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of pipeline gastrointestinal autoimmune diseases drug brazikumab to AstraZen
AbbVie and Roche's Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial that was supposed to confirm its efficacy.
The bad news from AbbVie’s full year results was that inflammatory diseases blockbuster Humira “only” made around $19.2 billion as ex-US sales were hit by cheaper biosimilar competitors.
